Jared Kaltwasser

Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The trial is one of 2 phase 3 studies of upadacitinib in patients with severe alopecia areata.

Patients with extramedullary disease had inferior progression-free survival.

Janus kinase inhibitors can be paired with corticosteroids or used as monotherapy in the treatment of alopecia areata.

Proceeding with hematopoietic stem cell transplantation (HSCT) is more cost-effective than delaying the procedure in patients with intermediate-risk acute myeloid leukemia (AML).

TACE combined with SBRT enhanced survival rates in patients with large hepatocellular carcinoma tumors, offering promising treatment insights.

A retrospective analysis found whole brain radiation therapy alongside immune checkpoint inhibitors led to “brilliant” 2-year overall survival rates.

Factors such as age, smoking status, and body mass index can help clinicians predict a patient’s risk of 30-day mortality.

Investigators found certain classes of prescriptions were also associated with outcomes, though they do not believe the association is necessarily a causal one.

TP53 mutations can have a significant impact on the prognosis of diseases like chronic lymphocytic leukemia, but their effect can vary based on numerous factors.

New data show midkine expression is heightened in small cell lung cancer, suggesting the growth factor may be an important therapeutic target.

Thirty-six immune cell phenotypes were flagged as having an association with idiopathic pulmonary fibrosis (IPF).

Switching to venetoclax led to sustained high rates of undetectable minimal residual disease, the investigators found.

The research showed that certain females—but not males—were at a higher risk of anxiety and depression.

Investigators found that Janus kinase inhibitors were effective in a dose-dependent manner.

Of 14 metabolites identified, 2 appeared to have “robust” causal relationships with idiopathic pulmonary fibrosis.

Older patients with small cell lung cancer and significant weight loss were more likely to experience dose interruptions than patients with cachexia.

Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.

The finding that basophil counts may have prognostic significance aligns with a growing body of research into basophils in myeloproliferative neoplasms.

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a higher percentage of regulatory T cells (Tregs).

Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.

The findings suggest a role for assessment of variant-carrying status to predict disease progression in idiopathic pulmonary fibrosis (IPF).

The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.

A deep learning generative model is capable of autonomously learning about idiopathic pulmonary fibrosis.

The genes are all associated with cellular senescence, which is believed to play an important role in the development of idiopathic pulmonary fibrosis (IPF).

Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) to a real-world cohort receiving standard therapy.

Patients with early-stage melanoma who experience relapse following wide local excision face worse survival outcomes.

Multi-hit TP53 mutations significantly worsened survival in patients with myeloproliferative neoplasms (MPNs) and acute myeloid leukemia (AML), revealing critical prognostic insights.

Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.